Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Roadman Investments Corp RMANF is trading once again...
$RVVTF ALERT COVID-19 | Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3
http://thestocksmarket.net/2020/07/31/alert-covid-19-revive-therapeutics-announces-u-s-fda-approval-of-confirmatory-phase-3/
Company is into Mushroom PSILOCYBIN therapy also ...
Anyone know when/if Roadman Investments RMANF will trade again?
WUHN - .24 up and hit with a big block. I'm still adding!
$WUHN having a strong session here
After looking at all of the Shroom stocks listed in the I-Box I would have to agree - WUHN has the best potential for gains from current levels.
Yes I have! $WUHN might be Creme de la Creme bro
Have you looked at the IBOX? If I missed anything, let me know.
Hey John do we have a comprehensive list of shroom stocks?
Home > Boards > US OTC > Medical - Healthcare > Numinus Wellness Inc. (LKYSD)
Here is an area of concern that should raise a red flag for anyone investing in US companies. I looks to me that rather than doing the right thing and brining in legislation that will help people heal, the feds are going to double down on the bs they keep reinforcing in the bogus war on drugs. This is why I am avoiding investments in the US. They are so entrenched in abusing their population and now we have 2 anti drug guys running for president so the abuse will continue. So sad they could have been very successful and led the world.
https://www.federalregister.gov/documents/2020/05/15/2020-09469/criteria-for-designation-of-emerging-drug-threats-in-the-united-states
Interview with SHRMF CEO Roger McIntyre https://psilocybinalpha.com/news/interview-with-roger-mcintyre-champignon-brands
There is a company I would like to put on the radar here, I have owned it for a while but they have just expanded their operation to include psychoactives. It started as New Wave Esports, they just did a 3:1 reverse split and changed their ticker from NWES to SPOR they bought Anahit pharma company. They are supposedly aiming to grow mushrooms and cannabis in Jamaica. They just completed the changes this week. I am going to keep what I have since if they actually execute, they will have online gaming, online betting, cannabis and mushrooms.... everything needed for staying at home and avoiding being sad. They do not have an ihub page and I do not have the talent to make one. I just wanted to let you folks know about them, so many here have given me wonderful tips over the years I just wanted to make you aware. I do not know the management. I saw an interview with Daniel Mitre last summer but he seems to have been shaken out by this new expansion from exclusively esports to the psilocybin and cannabis e sports combo.
Here is a link to the details of the deal.
https://thecse.com/en/listings/technology/new-wave-esports-corp
MindMed reports first quarter 2020 results
https://www.otcmarkets.com/stock/mmedf/news/MindMed-Reports-First-Quarter-2020-Results-and-Corporate-Update?id=262023
MMEDF NEWS 5/11/2020:
MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator
Signs Clinical Trial Agreement With Maastricht University In Netherlands
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
TORONTO, May 12, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED; OTC: MMEDF) ("MindMed" or the "Company") is pleased to announce that, on May 8, 2020, it has entered into a clinical trial agreement with Maastricht University to undertake a Phase 2a clinical trial for lysergic acid diethylamide ("LSD") in adult patients with Attention Deficit Hyperactivity Disorder ("ADHD"). MindMed previously established a microdosing division to develop a portfolio of clinical trials studying the use of sub-perceptual amounts of psychedelic substances for medical purposes.
As part of the agreement, Maastricht University will provide facilities and personnel for the Phase 2a Proof of Concept Clinical Trial for MindMed's multicentre, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of low dose LSD as treatment for ADHD in adults.
Dr. Kim Kuypers, associate professor, Department of Neuropsychology & Psychopharmacology at Maastricht University will serve as a Principal Investigator for the Phase 2a Clinical Trial. Dr. Kuypers is a leading clinical investigator in the field of psychedelics and has previously evaluated the concept of microdosing in other research. Her main goal as a clinical researcher is to understand the neurobiology underlying flexible cognition, empathy, and well-being.
MindMed is now advancing its LSD microdosing program with both Dr Kuypers and the previously announced partnership with University Hospital Basel's Liechti Lab. MindMed is currently in the regulatory ethics submission process in the Netherlands and plans to begin the Phase 2a clinical trial by the end of the year.
MindMed Co-Founder and Co-CEO, JR Rahn, said, "Working with Dr. Kim Kuypers, one of the leading research experts for microdosing of psychedelics, has the potential to help millions of adults through the development of innovations for coping and treating ADHD. Our work in the Netherlands will complement our existing collaboration with University Hospital Basel's Liechti Lab to better understand the therapeutic potential of microdosing."
MindMed Announces $10 Million Bought Deal Equity Financing to Fund University Hospital Basel Collaboration https://www.otcmarkets.com/stock/MMEDF/news?id=260991
MindMed Announces $10 Million Bought Deal Equity Financing to Fund University Hospital Basel Collaboration https://www.otcmarkets.com/stock/MMEDF/news?id=260991
The GrowthOp: Investors are jumping into psychedelics after learning hard lessons in cannabis industry.
https://www.thegrowthop.com/cannabis-news/investors-are-jumping-into-psychedelics-after-learning-hard-lessons-in-cannabis-industry
Where can you find?
So far MINDMED, CHAMPIGNON holding up.
Mind Med Webinar w/Kevin O’Leary and JR Rahn Highlights:
- Prior to investing, O’Leary’s team extensively look into Mind Med prior to investing. One of Mr. O’Leary’s employees liked the company so much that he got a loan from O’Leary for $15 million to invest. O’Leary then went and invested more because he said “I can’t have one of my employees investing more than me”.
- Absolutely no chance of recreational involvement. O’Leary made that clear so that institutional investors will be able to invest. Their goal is to achieve FDA approval and/or FDA fast-track approval through their clinical trials.
- No chance of liquidating shareholders in order to acquire any companies.
- They have a patent on a drug that neutralizes the effects of LSD.
- They are targeting microdosing LSD towards ADHD ($16 billion dollar a year industry) and anxiety/depression. JR Rahn said he got the idea to further research the applications of LSD when he was in silicon valley and had a lot of friends with ADHD who would microdose to treat and control their symptoms.
- They are targeting the drug 18-MC (derivative of ibogaine) to treat drug addiction (primarily aimed at treating opioid addiction) and alcohol abuse disorder. The application towards the treatment of opioid abuse disorder is where JR Rahn believes they may get Fast Track FDA approval if they see results because there are very few medications right now effective at treating opioid use disorder.
Please add more to this if you remember things. I was unable to listen to the entire webinar.
Top News Stories you guys may have missed. A good Way to catch up on News.
Cannabis Countdown: Top 10 Marijuana and Psychedelic Stock News Stories of the Week
News Is Here
https://www.thecannabisinvestor.ca/former-red-bull-canada-president-joins-champignon-brands-special-advisory-committee/?mc_cid=153345b111&mc_eid=bf9094a3b1
Former Red Bull Canada President Joins Champignon Brands’ Special Advisory Committee
APRIL 16, 2020
Champignon Brands Appoints Mr. Jim Bailey to the Company’s Special Advisory Committee
Mr. Bailey is the Former President of Red Bull Canada
Mr. Bailey Will Lead Champignon’s Marketing, Distribution and Commercialization of the Company’s Novo Formulations-Branded Novel Delivery Systems for the Pharmaceutical, Nutraceutical and Psychedelic Medicine Industries
Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FRA: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine has further bolstered its pharmaceutical, nutraceutical and CPG marketing/distribution competencies via the appointment of the former President of Red Bull Canada, Mr. Jim Bailey, to its Special Advisory Committee.
Mr. Bailey previously served as the Global Chief Marketing Officer for Merrell Outdoors, overseeing both product and consumer marketing with annual revenues of US$600M. Prior to his tenure at Merrel, Jim served as President of Red Bull Canada, playing an instrumental role in launching the Red Bull brand in Canada and growing the business to $150 million in annual revenue with over 300 employees nationwide.
“I am very excited to be part of a company that is leading the way in finding alternative solutions to traditional pharmaceuticals with science based research and functional products. My background in heavily regulated industries coupled with my experience in the CPG space provides a great compliment to an already talented and experienced advisory board,” commented Jim Bailey.
Mushroom Medicine to be made by CHampignon Brands.
Champignon Brands Is Turning Magic Mushrooms Into Medicine
SeekingAlpha Article here
Summary
Medical professionals are beginning to use psychedelics to treat a host of mental disorders.
Champignon Brands is growing a vertically integrated psychedelic drug company.
Other major competitors are using different drugs to treat different disorders, leaving Champignon more room to operate.
Investment Thesis
The never-ending quest of medical researchers seeking treatments for mental disorders has led them to, of all things, psychedelic drugs. Recent studies have shown these types of drugs have serious potential to treat common ailments like addiction, depression, post-traumatic stress disorder (PTSD), and obsessive-compulsive disorder (OCD).
Companies are starting to take notice of this multi-billion dollar opportunity and are beginning to develop drugs and perform widespread clinical studies, with the goal of bringing doctor-prescribed medications to market. One company that got its start in the functional food industry is making the leap into a full-blown drug developer.
Champignon Brands (OTCPK:SHRMF) (CSE:SHRM) completed its IPO earlier this year. The company's mission is "pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder, as well as substance and alcohol use disorders." The company intends to develop novel medications, run them through clinical trials and then receive regulatory approval to have them prescribed to patients in the U.S. and beyond.
Fungal Origins
While the end goal is to develop a novel medication, Champignon Brands got its start selling non-psychedelic, mushroom-infused consumer packaged good (CPG) products. Their first product was their Vitality Superteas. The company claims that the teas, which come in a variety of flavors and formulations, can assist with sleep, stress, and cognitive function.
Champignon is also partnering with a coffee company to develop a cold-brewed coffee product with many of the same infusions as their teas. Once finished, the product will be sold at the coffee company's cafe, as well through Champignon's online platform. Having the product available in a cafe will allow the company to better market the product and spread awareness through word of mouth advertising.
These are just the first of many products that management has in the pipeline. The company strongly believes in the functional food market and for good reason: the global functional food market is estimated at over $160 billion. Management intends to use the proceeds from their CPG division to help fund the R&D necessary to bring their psychedelic medicines to market.
Magic Medicine
To fast track their drug development pipeline, Champignon acquired Tassili Life Sciences Corp. Tassili has been partnering with the University of Miami to conduct research on using psilocybin to treat PTSD and traumatic brain injuries. The partnership allows for Tassili to keep any of the intellectual property developed from the studies. The company has thus far filed four provisional patent applications as a result of the research. The real money in this industry will be derived from patent-protected medications, so Champignon's acquisition of a company led by scientists familiar with developing medical intellectual property is crucial.
In order to save on costs and conduct more efficient research, the company intends to become as vertically integrated as possible. Their first step was acquiring craft mushroom grower Artisan Growers Ltd. The purchase gives Champignon a production facility capable of growing a variety of mushroom types in large quantities. The company intends to use this facility to produce feedstock for both its CPG products and their medicinal formulations. Having the growing facility in-house will give management better control over their product specifications, lowers costs, and gives researchers direct access to the product at all stages of the production process.
Champignon next decided to purchase Novo Formulations Ltd. Novo has developed proprietary drug delivery systems that better allow psychedelic drugs to interact with the human body. Champignon intends to use the systems to expand on their psilocybin drug development efforts. This should allow the company to achieve similar results while using less of the active ingredients in their medications, which will help margins down the road.
Most recently, Champignon acquired AltMed Capital Corp., which develops new drugs and operates a ketamine clinic. AltMed is led by Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto. Dr. McIntyre is widely regarded as one of the preeminent psychiatrists in the field of mood disorders. This move by Champignon gives it not only a leading world-renowned researcher but also someone who is actively using a psychedelic drug to treat people with mood disorders. Look for Dr. McIntyre to take a leading role in Champignon once AltMed is fully incorporated.
Competition
MindMed (OTCPK:MMEDF) (NEO:MMED) has been getting much fanfare recently for attracting investments from cannabis pioneer Bruce Linton and celebrity investor Kevin O'Leary. The psychedelic upstart's primary focus is its drug MC-18, a derivative of ibogain. MindMed is, currently, performing clinical studies on using the drug to treat opioid addiction and opioid withdrawal. The company is also performing clinical studies on using microdoses of lysergic acid diethylamid (LSD) to treat ADHD.
Revive Therapeutics (OTCPK:RVVTF) (CSE:RVV) has been exploring possible medical uses for cannabis and recently hopped on the psychedelic bandwagon. While MindMed and Champignon are focusing on mental disorders, Revive is focused on using psiliocybin and cannabidiol (CBD) to treat infectious diseases such as influenza and coronavirus.
While both of these companies are looking to use psychedelics as medicine, they're either using different drugs, treating different conditions or both. Champignon is establishing itself as the largest player in its own niche within the psychedelic medicine industry.
Risks
Federal Regulation: Psilocybin and other psychedelic drugs are still heavily regulated by the DEA, with many of them listed under Schedule 1 of the Controlled Substances Act. This scheduling severely limits the availability of these drugs to be studied for medical benefits and makes it much more difficult for a drug that is found to have medical benefits to be approved and accepted by the medical establishment. Investors should be aware that the psychedelic medicine industry will be hamstrung as long as these drugs are listed under Schedule 1.
Trading Volatility: Champignon Brands is both a micro-cap stock (market cap of between $50 million and $300 million) and a penny stock (stock price under $5 per share). Both of these labels are considered a negative for many investors as these types of companies are inherently more risky than larger companies. These types of companies tend to have a lower trading volume, leading to higher volatility. Potential investors should be prepared for large swings in share price, sometimes with no obvious catalyst.
New Company: Champignon is essentially a start-up. They've only just begun to assemble the pieces they will need to accomplish their goals. At a current valuation around $70 million (and growing, after the most recent acquisitions), Champignon comes at a hefty price tag for a company with little history or financial data to go on. MindMed, the largest company in the space, carries a market cap of over $150 million, thanks to its celebrity investors and a drug closer to the market. Whether either of these valuations is justified is largely based on where one thinks the science is going to lead. As of now, all signs are pointing to psychedelics having serious medicinal potential.
Conclusion
The story of medicinal psychedelics is still in its first chapter, there's still a long way to go until these drugs are being prescribed by doctors to treat specific ailments. The companies that will be successful when the industry matures will be those that have built a strong foundation, backed by proven products.
Champignon Brands is entering the market with a plan to develop life-changing medicines. Their focus on vertical integration and bringing in the best scientists in the field as, well as the establishment of their CPG division, make them an interesting option for less risk-adverse investors seeking to capitalize on the burgeoning psychedelic medicine industry.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Here’s How Psychedelic Medicine Could Help End the Opioid Epidemic Once and For All
-The Opioid Crisis Has Plagued North America for Decades, and According to the U.S. HHS, it Kills an Estimated 130+ People Per Day in the United States Alone
-Thanks to Recent Advancements in Psychedelic Medicine, There’s Renewed Hope and Optimism Surrounding the Deadly Epidemic
-ATAI Life Sciences, DemeRx and MindMed Are Waging War Against Opioid Addiction By Utilizing This One Little-Known Psychedelic Substance
The opioid crisis isn’t making as many headlines these days due to the rise of the COVID-19 pandemic, which has paralyzed much of the global economy and captivated the attention of billions worldwide. While the Coronavirus continues to sweep across the globe, a different type of epidemic continues to ravage America’s communities and families. We’re talking about the Opioid Epidemic.
CLick here to read the article
Champignon Brands to Acquire Health Canada Licensed Psychedelic Clinic Operator AltMed
Read News Here
Thanks for the chart!
I'm looking for the RMANF stock fuse getting lit!
They will have a nice little war chest. I hope they spend it wisely.
RMANF: CHECK OUT WHAT I FOUND, Pay attention to the bold: "On August 15, 2019, the Company acquired 1,500,000 units (“Champignon Unit”) of Champignon Brands Inc. (“Champignon”) for $150,000 which represented approximately 5.6% of the issued and outstanding common shares of Champignon. Each Champignon Unit consists of one common share of Champignon and one-half share purchase warrant. One full warrant is exercisable at $0.15 per share until August 15, 2022.... So they also have 750,000 warrants exercisable at $0.15 until August 15,2022 as well as the 1,000,000 shares
Roadman Investment Corp Financial Statement from 3/2/2020:
https://www.sedar.com/GetFile.do?lang=EN&docClass=5&issuerNo=00026391&issuerType=03&projectNo=03024919&docId=4676397
COPY AND PASTE THIS LINK AND THEN COMPLETE THE VERIFICATION CODE AT THE BOTTOM.
Yea I bet they are kicking themselves now for that sell, but owning 1 million shares is not bad.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |